SEC Comment Letter 0000000000-22-012678 to Aravive, Inc. (CIK 0001513818)
Aravive, Inc. (CIK 0001513818)
Date: Nov. 22, 2022 · CIK: 0001513818 · Accession: 0000000000-22-012678
AI Filing Summary & Sentiment
File numbers found in text: 333-268471
Letter
United States securities and exchange commission logo November 22, 2022 Gail McIntyre Chief Executive Officer Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, Texas 77098 Re:Aravive, Inc. Registration Statement on Form S-3 Filed November 18, 2022 File No. 333-268471 Dear Gail McIntyre: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow, Esq.
Show Raw Text
United States securities and exchange commission logo
November 22, 2022
Gail McIntyre
Chief Executive Officer
Aravive, Inc.
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, Texas 77098
Re:Aravive, Inc.
Registration Statement on Form S-3
Filed November 18, 2022
File No. 333-268471
Dear Gail McIntyre:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leslie Marlow, Esq.